Aptevo Therapeutics (APVO) Accounts Payables (2015 - 2026)

Aptevo Therapeutics (APVO) posted Accounts Payables of $890000.0 for Q1 2026, up 1.48% sequentially from $877000.0 in Q4 2025.

Aptevo Therapeutics (APVO) Accounts Payables (2015 - 2026) Analysis & Trends

Aptevo Therapeutics has reported Accounts Payables for 8 years, with the latest figure at $890000.0 in Q1 2026.

Quarterly Accounts Payables changed N/A year-over-year to $890000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $890000.0 (changed N/A YoY) and the FY2025 annual result came in at $877000.0, down 29.39% from the prior year.
Accounts Payables advanced to $890000.0 in Q1 2026 per APVO's latest filing, from $877000.0 in the prior quarter.
Over five years, Accounts Payables peaked at $1.2 million in Q4 2024 and troughed at $877000.0 in Q4 2025.
A 3-year average of $1.0 million and a median of $890000.0 in 2026 frame the typical range for Accounts Payables.
The widest YoY moves for Accounts Payables: up 29.39% in 2025, down 29.39% in 2025.
Over 3 years, Accounts Payables stood at $1.2 million in 2024, then decreased by 29.39% to $877000.0 in 2025, then increased by 1.48% to $890000.0 in 2026.
According to Business Quant data, Accounts Payables over the past three periods registered $890000.0, $877000.0, and $1.2 million for Q1 2026, Q4 2025, and Q4 2024 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Accounts Payables (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	429.50 Mn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	1.16 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	1.52 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	167.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	470.30 Mn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	108.02 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	622.65 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	428.93 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	35.57 Mn
10	Aptevo Therapeutics	3.18 Mn	-6.61 Mn	-	1.16 Mn

Download Data